TETRAULT LYNN A.
SEC CIK 1645512 · EDGAR
BoughtSold
Most active insiders at ALMS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | AKKARAJU SRINIVAS | Dir | $29.80M | $1.01M |
| 2 | Tananbaum James B. | Dir, 10% | $10.63M | — |
| 3 | Foresite Labs Fund I, L.P. | 10% | $7.53M | — |
| 4 | Foresite Labs, LLC | 10% | $7.00M | — |
| 5 | Foresite Labs Affiliates 2021, LLC | 10% | $3.63M | — |
| 6 | Foresite Capital Management VI LLC | 10% | $3.09M | — |
| 7 | Pangali Sanam | CLO | — | $176.0K |
| 8 | Schroer John R. | CFO | — | $86.5K |
| 9 | Hardiman Roy C. | Chief Business, Strategy Ofcr | — | $71.0K |
| 10 | Goldstein David M | CSO | — | $68.5K |
| 13 | TETRAULT LYNN A. | Dir | — | — |
Transactions 23
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-07-02 18:30 | 2026-06-30 | ALMS | ALUMIS INC. | TETRAULT LYNN A. | Dir | A - Grant | $0.00 | +3,553 | 3,553 | New | $0 |
| D | 2026-06-25 18:06 | 2026-06-23 | RYTM | RHYTHM PHARMACEUTICALS, INC. | TETRAULT LYNN A. | Dir | M - OptEx | — | +4,712 | 11.7K | +67% | — |
| DT | 2026-06-24 16:15 | 2026-06-22 | RYTM | RHYTHM PHARMACEUTICALS, INC. | TETRAULT LYNN A. | Dir | M - OptEx | $28.27 | +37.0K | 44.0K | +529% | +$1.05M |
| DT | 2026-06-24 16:15 | 2026-06-22 | RYTM | RHYTHM PHARMACEUTICALS, INC. | TETRAULT LYNN A. | Dir | S - Sale+OE | $100.32 | -37.0K | 7,000 | -84% | -$3.71M |
| T | 2026-06-17 16:07 | 2026-06-15 | NEO | NEOGENOMICS INC | TETRAULT LYNN A. | Dir | S - Sale | $11.10 | -5,307 | 86.1K | -6% | -$58.9K |
| T | 2026-06-11 16:10 | 2026-06-09 | NEO | NEOGENOMICS INC | TETRAULT LYNN A. | Dir | S - Sale | $11.29 | -5,307 | 91.4K | -5% | -$59.9K |
| D | 2026-06-03 19:47 | 2026-06-01 | NEO | NEOGENOMICS INC | TETRAULT LYNN A. | Dir | M - OptEx | $0.00 | +23.1K | 96.7K | +31% | $0 |
| D | 2025-06-23 | 2025-06-18 | RYTM | RHYTHM PHARMACEUTICALS, INC. | TETRAULT LYNN A. | Dir | M - OptEx | — | +4,000 | 7,000 | +133% | — |
| D | 2025-06-03 | 2025-06-01 | NEO | NEOGENOMICS INC | TETRAULT LYNN A. | Dir | M - OptEx | $0.00 | +12.3K | 73.7K | +20% | $0 |
| I | 2025-05-09 | 2025-05-09 | NEO | NEOGENOMICS INC | TETRAULT LYNN A. | Dir | P - Purchase | $8.14 | +7,000 | 7,000 | New | +$57.0K |
| DM | 2024-09-11 | 2024-09-09+ | RYTM | RHYTHM PHARMACEUTICALS, INC. | TETRAULT LYNN A. | Dir | M - OptEx | $11.82 | +20.7K | 13.0K | New | +$244.7K |
| DM | 2024-09-11 | 2024-09-09+ | RYTM | RHYTHM PHARMACEUTICALS, INC. | TETRAULT LYNN A. | Dir | S - Sale+OE | $49.71 | -20.7K | 3,350 | -86% | -$1.03M |
| D | 2024-08-28 | 2024-08-26 | RYTM | RHYTHM PHARMACEUTICALS, INC. | TETRAULT LYNN A. | Dir | S - Sale+OE | $50.01 | -4,300 | 3,000 | -59% | -$215.0K |
| D | 2024-08-28 | 2024-08-26 | RYTM | RHYTHM PHARMACEUTICALS, INC. | TETRAULT LYNN A. | Dir | M - OptEx | $18.99 | +4,300 | 7,300 | +143% | +$81.7K |
| DM | 2024-08-14 | 2024-08-12 | RYTM | RHYTHM PHARMACEUTICALS, INC. | TETRAULT LYNN A. | Dir | S - Sale+OE | $44.65 | -10.0K | 3,407 | -75% | -$446.5K |
| D | 2024-08-14 | 2024-08-12 | RYTM | RHYTHM PHARMACEUTICALS, INC. | TETRAULT LYNN A. | Dir | M - OptEx | $4.15 | +10.0K | 13.0K | +333% | +$41.5K |
| D | 2024-08-13 | 2024-08-10 | NEO | NEOGENOMICS INC | TETRAULT LYNN A. | Dir | M - OptEx | $0.00 | +11.3K | 61.4K | +23% | $0 |
| D | 2024-06-25 | 2024-06-21 | RYTM | RHYTHM PHARMACEUTICALS, INC. | TETRAULT LYNN A. | Dir | M - OptEx | — | +3,000 | 3,000 | New | — |
| 2024-03-06 | 2024-03-04 | NEO | NEOGENOMICS INC | TETRAULT LYNN A. | Dir | S - Sale | $15.97 | -6,112 | 50.1K | -11% | -$97.6K | |
| D | 2023-05-24 | 2023-05-22 | NEO | NEOGENOMICS INC | TETRAULT LYNN A. | Dir | M - OptEx | $11.60 | +1,507 | 56.2K | +3% | +$17.5K |
| D | 2022-06-14 | 2022-06-10 | NEO | NEOGENOMICS INC | TETRAULT LYNN A. | Dir | A - Grant | $0.00 | +15.6K | 54.7K | +40% | $0 |
| D | 2022-05-20 | 2022-05-18 | NEO | NEOGENOMICS INC | TETRAULT LYNN A. | Dir | M - OptEx | $7.27 | +3,334 | 39.1K | +9% | +$24.2K |
| D | 2021-10-13 | 2021-10-11 | NEO | NEOGENOMICS INC | TETRAULT LYNN A. | Dir | A - Grant | $0.00 | +838 | 35.8K | +2% | $0 |
Purchase Sale Sale after option exercise All abbreviations